Side effects of Sorafenib and sunitinib: A new concern for dermatologist and oncologist

Side effects of Sorafenib and sunitinib: A new concern for dermatologist and oncologist

Bibliographic Details
Main Authors:	Prachi Gole, Bhushan Madke, Uday Khopkar, Prabhash Kumar, Vanita Noronha, Monali Yadav
Format:	Article
Language:	English
Published:	Wolters Kluwer Medknow Publications 2014-01-01
Series:	Indian Dermatology Online Journal
Online Access:	http://www.idoj.in/article.asp?issn=2229-5178;year=2014;volume=5;issue=1;spage=89;epage=91;aulast=Gole

Similar Items

Dermatological side effects of epidermal growth factor receptor inhibitors: ′Pride′ complex
by: Bhushan Madke, et al.
Published: (2014-01-01)

Sorafenib and sunitinib: A dermatologist′s perspective
by: Vijendran Pragasam, et al.
Published: (2014-01-01)

Survey for geriatric assessment in practicing oncologists in India
by: Vanita Noronha, et al.
Published: (2019-01-01)

Rowell's syndrome in an Indian male and review of the literature
by: Bhushan Madke, et al.
Published: (2015-01-01)

Nephrogenic systemic fibrosis
by: Bhushan Madke, et al.
Published: (2011-01-01)

Dermoscopy in albinism
by: Mayuri Kalantri, et al.
Published: (2024-05-01)

Cutaneous protothecosis
by: Hershada S Mithari, et al.
Published: (2022-01-01)

Hyperkeratotic palmoplantar lichen planus in a child
by: Bhushan Madke, et al.
Published: (2013-01-01)

Indian dermatologists wield technology to combat COVID-19!
by: Deepak Jakhar, et al.
Published: (2020-01-01)

Microneedling with PRP for Acne Scars: A New Tool in Dermatologist Arsenal - A Scoping Review
by: Meghe Soham R, et al.
Published: (2024-04-01)

Oncologists' perceptions of the need for assessing individual domains in the geriatric assessment and worthwhile outcomes in treating older patients with cancer: A questionnaire-based survey
by: Vanita Noronha, et al.
Published: (2021-01-01)

Everolimus: the first approved product for patients with advanced renal cell cancer after sunitinib and/or sorafenib
by: Chris Coppin
Published: (2010-04-01)

Fibroepithelioma of Pinkus in continuity with nodular basal cell carcinoma: A rare presentation
by: Atul M Dongre, et al.
Published: (2016-01-01)

Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation
by: J Thompson Coon, et al.
Published: (2010-01-01)

Survey of the impact of BOLT-trial data on oncologists’ and dermatologists’ decision-making in treating patients with locally advanced basal cell carcinoma
by: Luigi Scarpato, et al.
Published: (2024-07-01)

All for one: Collaboration between dermatologist, radiation oncologist and radiologist in the clinical management of “difficult to treat” non melanoma skin cancer
by: Federico Gagliardi, et al.
Published: (2024-05-01)

Journey of the Patient With Melanoma: Understanding Resource Use and Bridging the Gap Between Dermatologist, Surgeon, and Oncologist in Different Health Care Systems
by: Cássia Rita Pereira da Veiga, et al.
Published: (2019-07-01)

The cure for a racing heart
by: Vanita Noronha, et al.
Published: (2013-01-01)

Association of toxicity of sorafenib and sunitinib for human keratinocytes with inhibition of signal transduction and activator of transcription 3 (STAT3).
by: Kazuhiro Yamamoto, et al.
Published: (2014-01-01)

Sites of disease as predictors of outcome in metastatic renal cell carcinoma patients treated with first-line sunitinib or sorafenib
by: Paolo Grassi, et al.
Published: (2015-04-01)

The analysis of the long-term outcomes of sorafenib therapy in routine practice in imatinib and sunitinib resistant gastrointestinal stromal tumors (GIST)*
by: Piotr Rutkowski, et al.
Published: (2017-12-01)

Comparison of efficacy and safety among axitinib, sunitinib, and sorafenib as neoadjuvant therapy for renal cell carcinoma: a retrospective study
by: Wen Cai, et al.
Published: (2019-10-01)

Postoperative Adjuvant Sorafenib or Sunitinib for Nonmetastatic Renal Cell Carcinoma with Venous Tumor Thrombus: a Prospective Cohort Study
by: Liangyou Gu, et al.
Published: (2017-12-01)

Treatment-related adverse effects with pazopanib, sorafenib and sunitinib in patients with advanced soft tissue sarcoma: a pooled analysis
by: Que Y, et al.
Published: (2018-07-01)

A dermatologist's visit to the community: An intriguing perspective
by: Anuja Yadav, et al.
Published: (2019-01-01)

Side effects of chronic systemic glucocorticoid therapy: what dermatologists should know
by: Lucas Campos Prudente Tavares, et al.
Published: (2024-04-01)

Dermatologists’ Knowledge and Attitude Toward Isotretinoin Ocular Side Effects in Egypt
by: Elshafie M, et al.
Published: (2021-09-01)

Zosteriform spiradenoma with spiradenocarcinoma: A rare entity
by: Satish A Adulkar, et al.
Published: (2015-01-01)

Authors' reply to thota and seshadri
by: Arshiya Sehgal, et al.
Published: (2024-01-01)

Authors' reply to Maskomani
by: Minit Shah, et al.
Published: (2023-01-01)

Authors' reply to Bhargav and Mayilvaganan
by: Saswata Saha, et al.
Published: (2023-01-01)

Authors' reply to Villarreal-Garza et al., Kelekar et al., Jacob et al., Pimple et al., Ghafur, and Potter
by: George Abraham, et al.
Published: (2021-01-01)

Authors' reply to Raja and Suryavanshi
by: Anuradha Chougule, et al.
Published: (2020-01-01)

Confusion worse confounded
by: Vanita Noronha, et al.
Published: (2013-01-01)

Authors' reply to Sansar et al. and Kumar
by: Akhil Kapoor, et al.
Published: (2021-01-01)

The changing landscape of hormonal therapy in castration-resistant prostate cancer
by: Amol Dongre, et al.
Published: (2012-01-01)

Authors' reply to Bhattacharya
by: Srigadha Vivek Kumar, et al.
Published: (2023-01-01)

Being an academic dermatologist in Turkey: Young academic dermatologists’ perspectives on dermatology
by: Sezgi Sarıkaya Solak, et al.
Published: (2021-03-01)

Sexual Health of Patients in Treatment for Lung Cancer: An Undercover Concern for Patients and Oncologists
by: Mafalda Costa, et al.
Published: (2025-02-01)

The dermatologists’ case for the bidet
by: Yoseph Dalia, MD, MBA, et al.
Published: (2023-10-01)